Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Cerebral Oxygen Metabolism in Adults with Sickle Cell Disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Quantification of cerebral perfusion and cerebrovascular reserve using Turbo-QUASAR arterial spin labeling MRI

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prospective motion correction in single voxel spectroscopy at 7T using fat navigators and higher order shimming

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

  • Lena VáclavŮ
  • Jan Petr
  • Esben Thade Petersen
  • Henri Jmm Mutsaerts
  • Charles Bl Majoie
  • John C Wood
  • Ed VanBavel
  • Aart J Nederveen
  • Bart J Biemond
Vis graf over relationer

In sickle cell disease (SCD), oxygen delivery is impaired due to anemia, especially during times of increased metabolic demand, and cerebral blood flow (CBF) must increase to meet changing physiologic needs. But hyperemia limits cerebrovascular reserve (CVR) and ischemic risk prevails despite elevated CBF. The cerebral metabolic rate of oxygen (CMRO 2) directly reflects oxygen supply and consumption and may therefore be more insightful than flow-based CVR measures for ischemic risk in SCD. We hypothesized that adults with SCD have impaired CMRO 2 at rest and that a vasodilatory challenge with acetazolamide would improve CMRO 2. CMRO 2 was calculated from CBF and oxygen extraction fraction (OEF), measured with arterial spin labeling and T 2-prepared tissue relaxation with inversion recovery (T 2-TRIR) MRI. We studied 36 adults with SCD without a clinical history of overt stroke, and nine healthy controls. As expected, CBF was higher in patients with SCD versus controls (mean ± SD: 74 ± 16 versus 46 ± 5 mL/100 g/min, P <.001), resulting in similar oxygen delivery (SCD: 377 ± 67 versus controls: 368 ± 42 μmol O 2/100g/min, P =.69). OEF was lower in patients versus controls (27 ± 4 versus 35 ± 4%, P <.001), resulting in lower CMRO 2 in patients versus controls (102 ± 24 versus 127 ± 20 μmol O 2/100g/min, P =.002). After acetazolamide, CMRO 2 declined further in patients (P <.01) and did not decline significantly in controls (P =.78), indicating that forcing higher CBF worsened oxygen utilization in SCD patients. This lower CMRO 2 could reflect variation between healthy and unhealthy vascular beds in terms of dilatory capacity and resistance whereby dysfunctional vessels become more oxygen-deprived, hence increasing the risk of localized ischemia.

TidsskriftAmerican Journal of Hematology
Udgave nummer4
Sider (fra-til)401-412
Antal sider12
StatusUdgivet - apr. 2020

ID: 59013068